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Summary
Background The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 
vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national 
vaccination programmes in the UK and several other countries. Studying the real-world effects of these vaccines is an 
urgent requirement. The aim of our study was to investigate the association between the mass roll-out of the first 
doses of these COVID-19 vaccines and hospital admissions for COVID-19.
Methods We did a prospective cohort study using the Early Pandemic Evaluation and Enhanced Surveillance 
of COVID-19—EAVE II—database comprising linked vaccination, primary care, real-time reverse transcription- 
PCR testing, and hospital admission patient records for 5·4 million people in Scotland (about 99% of the population) 
registered at 940 general practices. Individuals who had previously tested positive were excluded from the analysis. A 
time-dependent Cox model and Poisson regression models with inverse propensity weights were fitted to estimate 
effectiveness against COVID-19 hospital admission (defined as 1–adjusted rate ratio) following the first dose of 
vaccine. 
Findings Between Dec 8, 2020, and Feb 22, 2021, a total of 1 331 993 people were vaccinated over the study period. The 
mean age of those vaccinated was 65·0 years (SD 16·2). The first dose of the BNT162b2 mRNA vaccine was associated 
with a vaccine effect of 91% (95% CI 85–94) for reduced COVID-19 hospital admission at 28–34 days post-vaccination. 
Vaccine effect at the same time interval for the ChAdOx1 vaccine was 88% (95% CI 75–94). Results of combined 
vaccine effects against hospital admission due to COVID-19 were similar when restricting the analysis to those aged 
80 years and older (83%, 95% CI 72–89 at 28–34 days post-vaccination).
Interpretation Mass roll-out of the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines was associated with 
substantial reductions in the risk of hospital admission due to COVID-19 in Scotland. There remains the possibility 
that some of the observed effects might have been due to residual confounding.
Funding UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy 
Challenge Fund, Health Data Research UK.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In December, 2019, there was an outbreak of the novel 
SARS-CoV-2 in Wuhan, China, which was later declared as 
the COVID-19 pandemic by WHO. Since the beginning of 
the pandemic and as of April 20, 2021, more than 141 
million cases and 3 millions deaths have been reported in 
more than 223 countries and territories worldwide. The UK 
has among the highest morbidity and mortality rates world-
wide. Scotland has reported more than 24 000 hospital 
admissions and 7600 deaths due to COVID-19.1
Unprecedented investments have been made in vaccine 
technology, evaluation, and production in response to the 
pandemic. Authorisation of the first COVID-19 vaccines 
occurred soon after publication of the initial phase 3 
safety and efficacy studies,2 and the UK was one of the 
first countries to license these vaccines for use.1 As of 
April 13, 2021, first-dose vaccine coverage of about 50% 
has been reported in Scotland with more than 2·6 million 
vaccines administered across the Scottish population, 
and delivery targeted at specified priority groups of those 
most at risk of harm (including those aged 50 years and 
older and health-care workers; appendix p 1).1,3
Clinical trials of all three vaccines authorised for use in 
the UK (ie, Pfizer–BioNTech, Oxford–AstraZeneca, and 
Moderna) have reported high vaccine efficacy. For the 
Pfizer–BioNTech vaccine (BNT162b2 mRNA COVID-19 
vaccine), 95% efficacy was reported against laboratory-
confirmed COVID-19.4 The Oxford–AstraZeneca vaccine 
was found to have 70% efficacy against COVID-19 illness 
among seronegative participants.5 The Moderna vaccine 
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(mRNA-1273) was reported to have 94% efficacy against 
confirmed COVID-19 but, given that the first dose of 
mRNA-1273 was given in Scotland on April 7, 2021, it is 
therefore not included in this analysis.6
Large post-licensure epidemiological studies are needed 
to complement the findings of pre-licensure trials to 
estimate the effectiveness of these vaccines at the 
population level in real-world settings.7 The delayed 
second dose COVID-19 vaccination policy of the UK does 
not comply with the manufacturer guidance on timing 
between the first and second dose (ie, 21 days for 
Pfizer–BioNTech and 28 days for Oxford–AstraZeneca 
vaccines). Reflecting the need to gather evidence on this 
policy, we aimed to investigate the association between the 
first doses of the Pfizer–BioNTech and Oxford–AstraZeneca 
vaccines and hospital admissions in those with confirmed 
COVID-19 among high-risk adults in Scotland.
Methods
Study design and participants
We did an open, real-time prospective observational 
cohort study with national-level coverage in Scotland 
using a unique dataset consisting of linked vaccination, 
primary care, laboratory testing, hospital admission, and 
mortality data (appendix p 3). Data were available for 
5·4 million people in Scotland.8 Individuals who had 
previously tested positive with real-time reverse 
transcription-PCR (rtPCR) for SARS-CoV-2 infection 
before Dec 8, 2020, were excluded from this analysis. 
Ethical approval was obtained from the National Research 
Ethics Service Committee, Southeast Scotland 02 
(reference number, 12/SS/0201), and Public Benefit and 
Privacy Panel for Health and Social Care (reference 
number, 1920–0279). We produced a protocol before 
undertaking the analysis. We followed the Reporting of 
studies Conducted using Observational Routinely-
collected Data9 checklist to guide transparent reporting of 
this cohort study (appendix pp 16–23). Our analysis code 
has been made publicly available.
Procedures
By use of the Early Pandemic Evaluation and Enhanced 
Surveillance of COVID-19—EAVE II—database, primary 
care data derived from 940 general practices across 
Scotland were linked to the laboratory data from the 
Electronic Communication of Surveillance in Scotland 
(ECOSS),8 the hospital admission data available from the 
Scottish Morbidity Record 01 database, and Rapid 
Preliminary Inpatient Data.10 Vaccination data were 
available from general practices and the Turas Vaccination 
Management Tool (TVMT),11 which is a web-based tool to 
capture vaccinations in the community and create real-
time vaccination records. Laboratory data from ECOSS 
included all rtPCR test results from both National Health 
Service laboratories (Pillar 1) and Lighthouse Government 
laboratories (Pillar 2).12 Data were deterministically 
linked using the Community Health Index number, 
which is a unique identifier used for all health-care 
contact across Scotland.8
We studied the first doses of the BNT162b2 mRNA 
COVID-19 (also known as the Pfizer–BioNTech) vaccine4 
and ChAdOx1 (AZD1222; also known as the Oxford–
AstraZeneca) vaccine.5 An individual was defined as 
exposed if they received a single dose of vaccine between 
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Research in context
Evidence before this study
We searched PubMed, medRxiv, and SSRN for observational 
studies, with no language restrictions, using the term “COVID-19 
vaccine effect”. We searched for studies published between 
Dec 1, 2020, and March 2, 2021. We found one study from Israel, 
which included 596 618 individuals who received the 
BNT162b2 mRNA (Pfizer–BioNTech) vaccine and an equal number 
of controls. The study showed that 14–20 days after the first 
vaccination dose there was a vaccine effect of 74% (95% CI 56–86) 
for hospital admissions due to COVID-19. Public Health England 
has reported that the first dose vaccine effect against hospital 
admissions due to COVID-19 for the BNT162b2 mRNA and 
ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines is about 80%.
Added value of this study
Current Scottish (UK) policy for use of vaccines against 
COVID-19 involves an offer of a first dose followed by a second 
dose 12 weeks later. To our knowledge, this is the first study of 
COVID-19 vaccine effect against hospital admissions for an 
entire nation after a single dose of vaccine. We found that a 
single dose of the BNT162b2 mRNA COVID-19 vaccine was 
associated with a vaccine effect of 91% (95% CI 85–94) for 
hospital admissions due to COVID-19 28–34 days after 
vaccination. A single dose of ChAdOx1 vaccine was associated 
with a vaccine effect of 88% (95% CI 75–94) at 28–34 days post-
vaccination. Comparable vaccine effects were seen in those aged 
80 years and older against hospital admissions due to COVID-19 
with a high combined vaccine effect of 83% (95% CI 72–89) at 
28–34 days after vaccination. For the same age group (≥80 years 
old) and at the same post-vaccination period (28–34 days), a 
vaccine effect of 88% (95% CI 76–94) was found for the 
BNT162b2 mRNA vaccine and 81% (60–91) for the ChAdOx1 
vaccine.
Implications of all the available evidence
We provide national evidence that the mass roll-out of first 
doses of the COVID-19 vaccines currently being used in the UK 
vaccination programme was associated with substantial 
reductions in risk of COVID-19 hospital admissions in the 
populations at highest risk for severe COVID-19 outcomes. 
However, we note that some of the observed effects might 
have been due to residual confounding.
For the publicly available 
analysis code see https://github.
com/EAVE-II/Covid-VE
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Dec 8, 2020, and Feb 22, 2021, with maximum follow-up 
time censored at Feb 22, 2021 (the latest event date). 
Vaccinated groups were stratified by time intervals 
including 0–6, 7–13, 14–20, 21–27, 28–34, 35–41, and 
42 or more days post-vaccination, and by the type of 
vaccine received. Vaccination information was extracted 
from the general practitioner records and the 
TVMT system and included individuals vaccinated in 
general practices, community vaccination hubs, and 
other settings such as care homes.
The primary outcome was vaccine effect, assessed as 
hospital admissions with COVID-19 as the main cause of 
admission, or hospital admission within 28 days of a 
positive rtPCR test for SARS-CoV-2 infection from 
Dec 8, 2020, to Feb 22, 2021. International Classification 
of Diseases-10 codes used for COVID-19 illness are 
presented in the appendix (p 5). A post-hoc sensitivity 
analysis was also carried out to assess any vaccine 
programme effects or residual confounding effects 
during the early post-vaccination period. An additional 
post-hoc exploratory ecological analysis was done to 
investigate the effect of lockdown measures on hospital 
admissions between September, 2020, and February, 2021.
Statistical analysis
The primary analyses included vaccine effect estimates 
for vaccination status overall and for each vaccine type. 
The secondary analysis included vaccine effect estimates 
for vaccine status overall and for each vaccine type 
stratified by age groups (ages 18–64, 65–79, and 
≥80 years). These were grouped to the completed year 
(ie, 64·5 years would be categorised as 18–64 years and 
79·4 as 65–79 years).
Baseline characteristics in the vaccinated and 
unvaccinated groups were described using proportions. 
We assessed the effect of one dose of either vaccine 
against hospital admissions due to laboratory-confirmed 
SARS-CoV-2 infection, or clinical diagnosis of COVID-19 
on admission. Poisson regression adjusting for an offset 
representing the time at risk and time-dependent 
Cox models (considering the time at risk) were used to 
derive the rate ratios, hazard ratios, and 95% CIs for the 
association of vaccination with COVID-19 hospital 
admissions.
Cox models included spline terms for age and number 
of rtPCR tests before vaccination (a marker for health-
care workers, social-care workers, and care home 
residents who had repeated tests). Additional 
adjustments were made for sex, socioeconomic status, 
and underlying medical conditions at risk of COVID-19 
illness with vaccination groups representing a time-
dependent covariate. Calendar time intervals by week 
were included as stratification variables because the 
background epidemic was changing rapidly over the 
observation period. Poisson regression was used for the 
full adjustment and propensity weighting. This 
regression model used age groups in 5-year intervals as 
well as sex, deprivation, and number of previous tests. 
Additionally, the following comorbidity groups, all of 
which are associated with an increased risk of hospital 
admission, were included: type 1 and type 2 diabetes, 
high and low blood pressure, chronic obstructive 
pulmonary disease, chronic kidney disease, dementia, 
stroke, learning disorders, fractures, neurological 
conditions, chronic cardiac failure, asthma, epilepsy, 
blood cancer, liver cirrhosis, venous thromboembolism, 
peripheral vascular disease, atrial fibrillation, pulmonary 
Figure 1: COVID-19 vaccine uptake
(A) Uptake over time by age group. (B) Uptake by age and vaccine type.
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hypertension, Parkinson’s disease, rare pulmonary 
disorders, rheu matoid arthritis, and systemic lupus 
erythematosus.
Both the Cox models and Poisson regression used 
sampling weights, which were used to correct for the 
size of the registered general practice population being 
Vaccinated Unvaccinated 
(n=3 077 595)











Female 799 765 (60·0%) 456 667 (64·2%) 343 098 (55·3%) 1 481 142 (48·1%) 799 765/2 280 907 (35·1%)
Male 532 228 (40·0%) 255 172 (35·8%) 277 056 (44·7%) 1 596 453 (51·9%) 532 228/2 128 681 (25·0%)
Age group, years
18–64 470 960 (35·4%) 359 434 (50·5%) 111 526 (18·0%) 2 913 484 (94·7%) 470 960/3 384 444 (13·9%)
65–79 651 924 (48·9%) 315 620 (44·3%) 336 304 (54·2%) 107 022 (3·5%) 651 924/758 946 (85·9%)
≥80 209 109 (15·7%) 36 785 (5·2%) 172 324 (27·8%) 57 089 (1·9%) 209 109/266 198 (78·6%)
Socioeconomic status*
1 225 951 (17·0%) 126 858 (17·8%) 99 093 (16·0%) 640 087 (20·8%) 225 951/866 038 (26·1%)
2 259 785 (19·5%) 140 337 (19·7%) 119 448 (19·3%) 606 554 (19·7%) 259 785/866 339 (30·0%)
3 279 616 (21·0%) 142 783 (20·1%) 136 833 (22·1%) 593 487 (19·3%) 279 616/873 103 (32·0%)
4 283 288 (21·3%) 151 265 (21·2%) 132 023 (21·3%) 592 476 (19·3%) 283 288/875 764 (32·0%)
5 276 680 (20·8%) 146 461 (20·6%) 130 219 (21·0%) 609 927 (19·8%) 276 680/886 607 (31·2%)
Unknown 6673 (0·5%) 4135 (0·6%) 2538 (0·4%) 35 064 (1·1%) 6673/41 737 (16·0%)
Residential settlement†
1 398 251 (29·9%) 217 396 (30·5%) 180 855 (29·2%) 1 192 363 (38·7%) 398 251/1 590 644 (25·0%)
2 499 274 (37·5%) 279 933 (39·3%) 219 341 (35·4%) 1 052 938 (34·2%) 499 274/1 552 212 (32·2%)
3 133 842 (10·0%) 68 411 (9·6%) 65 431 (10·6%) 269 309 (8·8%) 133 842/403 151 (33·2%)
4 79 993 (6·0%) 36 623 (5·1%) 43 370 (7·0%) 131 373 (4·3%) 79 993/211 366 (37·8%)
5 129 389 (9·7%) 62 956 (8·8%) 66 433 (10·7%) 263 175 (8·6%) 129 389/392 564 (33·0%)
6 84 571 (6·3%) 42 385 (6·0%) 42 186 (6·8%) 133 373 (4·3%) 84 571/217 944 (38·8%)
Unknown 6673 (0·5%) 4135 (0·6%) 2538 (0·4%) 35 064 (1·1%) 6673/41 737 (16·0%)
Number of comorbidities
0 561 329 (42·1%) 358 088 (50·3%) 203 241 (32·8%) 2 086 239 (67·8%) 561 329/2 647 568 (21·2%)
1 379 133 (28·5%) 201 507 (28·3%) 177 626 (28·6%) 723 055 (23·5%) 379 133/1 102 188 (34·4%)
2 204 988 (15·4%) 86 722 (12·2%) 118 266 (19·1%) 192 945 (6·3%) 204 988/397 933 (51·5%)
3 102 835 (7·7%) 37 374 (5·3%) 65 461 (10·6%) 51 005 (1·7%) 102 835/153 840 (66·8%)
4 49 289 (3·7%) 16 700 (2·3%) 32 589 (5·3%) 15 763 (0·5%) 49 289/65 052 (75·8%)
≥5 34 419 (2·6%) 11 448 (1·6%) 22 971 (3·7%) 8589 (0·3%) 34 419/43 008 (80·0%)
Type of comorbidity
Asthma 175 171 (13·2%) 91 175 (12·8%) 83 996 (13·5%) 384 091 (12·5%) 175 171/559 262 (31·3%)
Chronic kidney condition‡ 
(stage 3)
133 393 (10·0%) 41 172 (5·8%) 92 221 (14·9%) 28 140 (0·9%) 133 393/161 533 (82·6%)
Liver cirrhosis 11 821 (0·9%) 5075 (0·7%) 6746 (1·1%) 11 518 (0·4%) 11 821/23 339 (50·6%)
Chronic neurological condition 8395 (0·6%) 3413 (0·5%) 4982 (0·8%) 9718 (0·3%) 8395/18 113 (46·3%)
Heart failure 35 998 (2·7%) 11 016 (1·5%) 24 982 (4·0%) 12 103 (0·4%) 35 998/48 101 (74·8%)
Diabetes (type 1) 6840 (0·5%) 3651 (0·5%) 3189 (0·5%) 14 582 (0·5%) 6840/21 422 (31·9%)
Diabetes (type 2) 156 720 (11·8%) 64 426 (9·1%) 92 294 (14·9%) 101 821 (3·3%) 156 720/258 541 (60·6%)
Dementia 32 317 (2·4%) 16 993 (2·4%) 15 324 (2·5%) 5493 (0·2%) 32 317/37 810 (85·5%)
Coronary heart disease 146 465 (11·0%) 52 895 (7·4%) 93 570 (15·1%) 55 643 (1·8%) 146 465/202 108 (72·5%)
Smoking status
Ex-smoker 277 240 (20·8%) 123 234 (17·3%) 154 006 (24·8%) 291 792 (9·5%) 277 240/569 032 (48·7%)
Smoker 312 302 (23·4%) 162 076 (22·8%) 150 226 (24·2%) 595 547 (19·4%) 312 302/907 849 (34·4%)
Non-smoker 510 325 (38·3%) 281 309 (39·5%) 229 016 (36·9%) 1 167 424 (37·9%) 510 325/1 677 749 (30·4%)
Unknown 232 126 (17·4%) 145 220 (20·4%) 86 906 (14·0%) 1 022 833 (33·2%) 232 126/1 254 959 (18·5%)
(Table 1 continues on next page)
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greater than the population in Scotland (some due to 
recently deceased patients still being recorded in the 
patient records and individuals who had recently 
moved). These weights were derived by matching the 
age and sex numbers in the general practice data to 
the Scottish population data. This adjustment ensured 
that the denominators in the tables matched the 
Scottish population.
The models were fit to a dataset with all events and a 
random sample, without replacement, of 100 individuals 
per event with sample weights calculated to represent 
the sampling fraction and thus ensure the correct 
calculation of the person-years at risk for the whole 
population. A combined weight was used in the 
statistical modelling. Finally, a propensity model for 
vaccination was developed using a logistic regression 
model including terms for age group by sex interaction, 
socioeconomic status, number of previous rtPCR tests, 
and number of clinical risk groups. The parameter 
estimates of this model were obtained from a 
25% sample of the cohort and the propensity score 
calculated for the whole cohort. Inverse propensity 
score weights were used as a final adjustment in the 
regression models.13
33 834 individuals received a second dose of the vaccine. 
Individuals who received two doses remained in the 
analysis for as long as they had one dose and were then 
censored at the date of the second dose. All statistical 
tests were two-tailed with a 5% significance level of p less 
than 0·05.
At the baseline of our cohort (Dec 8, 2020), several 
population characteristics that could potentially confound 
the association between COVID-19 vaccination and the 
outcomes of interest were determined. These included 
age, sex, socioeconomic status measured by quintiles of 
the Scottish Index of Multiple Deprivation (1 refers to 
most deprived and 5 refers to least deprived),8 residential 
settlement measured by the urban or rural 6-fold 
classification (1 refers to large urban areas and 6 refers to 
small remote rural areas),8 and the number and types of 
comorbidities commonly associated with COVID-19 
illness.8 To adjust for the residual confounding in which 
vaccines were not offered to or were declined by the most 
frail, we included a functional variable, namely dementia, 
in our covariate adjustment.14
We did several post-hoc sensitivity analyses to assess 
possible vaccine programme or residual confounding 
effects during the early period after vaccination (ie, 
<14 days when immunity should still be mounting).4 In 
particular, we carried out a falsification of exposure 
sensitivity analysis that involved re-running the analysis 
using a fictional date of vaccination 2 months before 
actual vaccination to determine the extent to which 
Vaccinated Unvaccinated 
(n=3 077 595)










(Continued from previous page)
Blood pressure (systolic/diastolic)
Very high (>160/100 mm Hg) 39 468 (3·0%) 16 872 (2·4%) 22 596 (3·6%) 44 656 (1·5%) 39 468/84 124 (46·9%)
High (141–160/91–100 mm Hg) 182 220 (13·7%) 80 785 (11·3%) 101 435 (16·4%) 216 560 (7·0%) 182 220/398 780 (45·7%)
Normal (110–140/65–90 mm Hg) 855 123 (64·2%) 452 231 (63·5%) 402 892 (65·0%) 1 497 236 (48·6%) 855 123/2 352 359 (36·4%)
Low (<110/65 mm Hg) 13 006 (1·0%) 7130 (1·0%) 5876 (0·9%) 40 673 (1·3%) 13 006/53 679 (24·2%)
Unknown 158 199 (11·9%) 98 989 (13·9%) 59 210 (9·5%) 673 071 (21·9%) 158 199/831 270 (19·0%)
No investigation 83 977 (6·3%) 55 832 (7·8%) 28 145 (4·5%) 605 400 (19·7%) 83 977/689 377 (12·2%)
Data are n (%) or n/N (%). *1 indicates most deprived, 5 indicates least deprived. †1 indicates a large urban area, 6 indicates a remote rural area. ‡Stage 3 chronic kidney 
disease refers to an estimated glomerular filtration rate of 30–59 mL per min.
Table 1: Baseline characteristics by vaccine status
Figure 2: COVID-19 hospital admissions over time by age group
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vaccine programme effects contributed to residual 
confounding. We have provided the overall predicted 
curves from the Cox proportional hazards model 
adjusting for covariates, with a stratification by calendar 
period (appendix pp 6–7). An over-dispersed Poisson 
regression model was also carried out to assess the effect 
of the national lockdown on Dec 26, 2020, and the 
additional restrictions imposed on Jan 5, 2021, on 
hospital admissions due to COVID-19 in adults 
(age 18–64, 65–79, and 80 or older).
The analyses were carried out by one statistician (CR) 
and independently checked by a second statistician (EM). 
All statistical analyses were done with statistical 
software R (version 3.6.1).
There was missing data for deprivation, urban-rural 
status (patient postcode was not available), smoking 
status, and blood pressure (value had not been recorded). 
Missing data were handled by creating a separate group 
for these individuals.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or the writing 
of the report.
Results
Between Dec 8, 2020, and Feb 15, 2021, 1 331 993 
(30%) of 4 409 588 adults aged 18 years or older were 
vaccinated in our study. Rapid uptake of the 
BNT162b2 mRNA and ChAdOx1 vaccines was observed 
over the study period (figure 1; table 1), with 65–79 years 
the age group with the highest uptake (85·9%; 651 942 
of 758 946). For the BNT162b2 mRNA vaccine, the highest 
uptake was found in patients younger than 65 years, 
whereas for the ChAdOx1 vaccine, highest vaccine uptake 
was found in patients aged 65–79 years (table 1). Vaccine 
uptake for both vaccines combined was higher in 
women (35·1%, 799 765 of 2 280 907 vs 25·0%, 532 228 of 
2 128 681 men). A low socioeconomic status was associated 
with lower vaccination rates than was a high socioeconomic 
status (level 1, 26·1% vs levels 3–5, 31·2–32·0%). Those 
living in large urban areas had an uptake of 25%, which 
was lower than all other residential categories. Vaccine 
coverage increased with the number of comorbidities, 
from 21·2% with none to 80·0% with five or more. 
Ex-smokers had a coverage of 48·7%, which was higher 
than the similar uptake recorded for both smokers and 
non-smokers. Vaccine coverage also increased with 
increasing blood pressure. These differences in the 
clinical factors were probably associated with age. Baseline 
characteristics of participants older than 80 years by 
vaccine status and timing are presented in the appendix 
(pp 10–12).
There was an overall downturn in the number of 
COVID-19 admissions to hospital over the study period 
(figure 2). This overall effect was not due to the vaccination 
programme because a downward trend was observed 
before mass vaccination. However, by use of an over-
dispersed Poisson regression model, we note that hospital 
admissions declined more markedly in those aged 80 years 
and older, who were the first to be vaccinated and of  whom 
50% had been vaccinated by the end of the third week in 
January, 2021,  compared with those aged 18–64 years, and 
that rate of decline accelerated in those aged 80 years and 
older (figure 3; appendix pp 13–14).
We found that vaccine effect at 28–34 days post-
vaccination against COVID-19 hospital admissions 
among those receiving the first dose of the vaccine 
BNT162b2 was 91% (95% CI 85–94) and for ChAdOx1 
was 88% (75–94; table 2).
Similar findings were observed in a pooled analysis 
for both vaccines against COVID-19 hospital admissions 
stratified by age group (table 3). At 28–34 days after 
vaccination, the vaccine effect estimate for those aged 
18–64 years was 92% (95% CI 82–97) and for those aged 
65–79 years was 93% (73–98). Vaccine effect for those 
aged 80 years and older at 28–34 days was 83% (95% CI 
72–89).
Among those aged 80 years and older at 28–34 days post-
vaccination, vaccine effect against COVID-19 hospital 
admission for those who received the first dose of the 
BNT162b2 mRNA vaccine was 88% (95% CI 76–94), and 
for ChAdOx1 was 81% (60–91; table 3).
The falsification analysis involving shifting the vacci-
nation date back 2 months to a period when vaccination 
could not have had an effect showed no difference between 
the vaccinated and unvaccinated groups over the whole 
follow-up period (appendix pp 6–9). 
Figure 3: COVID-19 hospital admissions by age group from September, 2020, to February, 2021
The black dotted vertical line represents the start of vaccination (Dec 8, 2020) and the blue dotted lines represent 
the two lockdowns on Dec 26, 2020, and Jan 5, 2021. The smooth lines are obtained from fitting a generalised 
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Discussion
This national prospective cohort study comprising 
almost the entire Scottish population found that the 
mass roll-out of the first doses of the BNT162b2 mRNA 
or ChAdOx1 vaccines was associated with protection 
against COVID-19 admis sion to hospital. A vaccine 
effect of 91% for the BNT162b2 mRNA vaccine and 
88% for the ChAdOx1 vaccine were found against 
COVID-19 hospital admissions at 28–34 days after 
vaccination. In the oldest age group (≥80 years), on the 
basis of a pooled analysis for both vaccines, we observed 
a vaccine effect of 83% against COVID-19 hospital 
admissions at this same timepoint. For the same age 
group and at the same time, a vaccine effect of 88% was 
found for the BNT162b2 mRNA vaccine, and 81% for the 
ChAdOx1 vaccine.
A study from Israel (Clalit Health Services) has 
reported on the vaccine effect of BNT162b2 mRNA. An 
analysis of data on more than 1·1 million individuals 
showed that after the first dose of vaccination, an 
effect of 74% was found 14–20 days after immunisation 
and an effect of 78% was found 21–27 days after 
immunisation against SARS-CoV-2 hospital admission.15 
Public Health England has reported that single dose 
vaccine effects against hospital admission for BNT162b2 
mRNA and ChAdOx1 were 80%.16 Complementary to 
these studies, we found a similar vaccine effect against 
COVID-19 hospital admission for the BNT162b2 mRNA 
and ChAdOx1 vaccines after a single dose.
This is, to our knowledge, the first national population-
level study assessing the programme effect of currently 
licensed COVID-19 vaccines on a severe COVID-19 
outcome. Our study has several strengths. We developed 
a national linked dataset and have created a platform that 
allowed rapid access to and analysis of data on vaccination 
status and medical condition status from routinely 
collected electronic health record data and national 
databases.8,17 This study is therefore less susceptible to 






Full and inverse 
propensity weighting 




Unvaccinated 831 226 7698 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 19 917 156 0·43 (0·37 to 0·50) 0·38 (0·32 to 0·44) 0·25 (0·21 to 0·29) 75% (71 to 79)
Vaccine dose 1 (7–13 days)§ 19 690 258 0·67 (0·59 to 0·76) 0·63 (0·56 to 0·72) 0·46 (0·41 to 0·52) 54% (48 to 59)
Vaccine dose 1 (14–20 days) 13 426 154 0·54 (0·46 to 0·63) 0·51 (0·43 to 0·60) 0·33 (0·28 to 0·39) 67% (61 to 72)
Vaccine dose 1 (21–27 days) 9119 72 0·37 (0·29 to 0·46) 0·33 (0·26 to 0·42) 0·24 (0·19 to 0·30) 76% (70 to 81)
Vaccine dose 1 (28–34 days) 6252 30 0·25 (0·17 to 0·36) 0·21 (0·15 to 0·30) 0·11 (0·08 to 0·17) 89% (83 to 92)
Vaccine dose 1 (35–41 days) 3822 21 0·36 (0·23 to 0·55) 0·23 (0·15 to 0·36) 0·22 (0·15 to 0·32) 78% (68 to 85)
Vaccine dose 1 (42+ days) 6047 32 0·51 (0·36 to 0·72) 0·28 (0·19 to 0·40) 0·26 (0·19 to 0·35) 74% (65 to 81)
BNT162b2 (Pfizer–BioNTech)
Unvaccinated 734 031 6671 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 10 517 34 0·18 (0·13 to 0·25) 0·15 (0·10 to 0·21) 0·14 (0·10 to 0·19) 86% (81 to 90)
Vaccine dose 1 (7–13 days)§ 10 991 119 0·57 (0·48 to 0·69) 0·42 (0·35 to 0·51) 0·47 (0·41 to 0·55) 53% (45 to 59)
Vaccine dose 1 (14–20 days) 7684 71 0·51 (0·40 to 0·64) 0·31 (0·24 to 0·39) 0·31 (0·25 to 0·38) 69% (62 to 75)
Vaccine dose 1 (21–27 days) 5672 38 0·41 (0·30 to 0·57) 0·21 (0·15 to 0·29) 0·22 (0·17 to 0·29) 78% (71 to 83)
Vaccine dose 1 (28–34 days) 4585 19 0·26 (0·16 to 0·40) 0·13 (0·08 to 0·21) 0·09 (0·06 to 0·15) 91% (85 to 94)
Vaccine dose 1 (35–41 days) 3292 20 0·40 (0·26 to 0·62) 0·18 (0·11 to 0·28) 0·22 (0·15 to 0·31) 78% (69 to 85)
Vaccine dose 1 (42+ days) 5996 31 0·38 (0·26 to 0·54) 0·20 (0·14 to 0·28) 0·23 (0·17 to 0·32) 77% (68 to 83)
ChAdOx1 (Oxford–AstraZeneca)
Unvaccinated 743 142 7252 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 9222 122 0·46 (0·38 to 0·55) 0·43 (0·35 to 0·51) 0·28 (0·23 to 0·34) 72% (66 to 77)
Vaccine dose 1 (7–13 days)§ 8699 139 0·48 (0·41 to 0·57) 0·53 (0·44 to 0·63) 0·32 (0·27 to 0·39) 68% (61 to 73)
Vaccine dose 1 (14–20 days) 5742 83 0·38 (0·30 to 0·47) 0·47 (0·37 to 0·58) 0·27 (0·21 to 0·34) 73% (66 to 79)
Vaccine dose 1 (21–27 days) 3447 34 0·23 (0·16 to 0·32) 0·31 (0·22 to 0·44) 0·19 (0·13 to 0·28) 81% (72 to 87)
Vaccine dose 1 (28–34 days) 1666 11 0·15 (0·08 to 0·26) 0·21 (0·12 to 0·39) 0·12 (0·06 to 0·25) 88% (75 to 94)
Vaccine dose 1 (35–41 days) 530 ≤5 0·04 (0·01 to 0·29) 0·06 (0·01 to 0·44) 0·03 (0·00 to 0·37) 97% (63 to 100)
Vaccine dose 1 (42+ days) 51 ≤5 0·44 (0·06 to 3·10) 0·68 (0·10 to 4·87) 0·41 (0·04 to 3·96) 59% (–296 to 96)
Poisson regression was used to provide all adjusted estimates. Individuals who had previously tested positive were excluded. RR=rate ratios. NA=not applicable. rtPCR=real-
time reverse-transcription-PCR. *Adjusted for age. †Adjusted for time (in weeks), age, sex, Scottish Index of Multiple Deprivation, number of rtPCR tests before vaccination, 
and number of underlying medical conditions. ‡Adjusted for time (in weeks), age, sex, Scottish Index of Multiple Deprivation, number of rtPCR tests before vaccination, 
number of underlying medical conditions, and inverse propensity of being vaccinated. §Any effects observed in less than 14 days are mainly due to vaccine programme effects.
Table 2: COVID-19 hospital admissions and days post-vaccination by vaccination status and type
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recall or misclassification bias than are studies of 
samples of the population. The use of a large population 
aided study power, facilitating estimation of vaccine 
effect in multiple age groups and time intervals after the 
first dose of the vaccination. We are likely to have 
excellent generalisability across the UK and potentially 






Full and inverse 
propensity weighting 





Unvaccinated 66 1 060 3442 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 6720 18 0·40 (0·25 to 0·64) 0·28 (0·18 to 0·46) 0·38 (0·29 to 0·50) 62% (50 to 71)
Vaccine dose 1 (7–13 days)§ 6667 55 1·29 (0·99 to 1·69) 0·88 (0·66 to 1·16) 1·10 (0·93 to 1·31) –10% (–31 to 7)
Vaccine dose 1 (14–20 days) 5458 25 0·77 (0·52 to 1·14) 0·49 (0·33 to 0·74) 0·58 (0·45 to 0·75) 42% (25 to 55)
Vaccine dose 1 (21–27 days) 4769 12 0·43 (0·24 to 0·76) 0·27 (0·15 to 0·49) 0·38 (0·27 to 0·54) 62% (46 to 73)
Vaccine dose 1 (28–34 days) 3859 ≤5 0·13 (0·04 to 0·41) 0·09 (0·03 to 0·27) 0·08 (0·03 to 0·18) 92% (82 to 97)
Vaccine dose 1 (35–41 days) 2797 7 0·43 (0·20 to 0·90) 0·26 (0·12 to 0·56) 0·40 (0·25 to 0·62) 60% (38 to 75)
Vaccine dose 1 (42+ days) 5166 11 0·37 (0·20 to 0·66) 0·24 (0·13 to 0·45) 0·35 (0·24 to 0·51) 65% (49 to 76)
65–79 years
Unvaccinated 132 254 2449 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 9598 42 0·23 (0·17 to 0·31) 0·26 (0·19 to 0·35) 0·12 (0·08 to 0·17) 88% (83 to 92)
Vaccine dose 1 (7–13 days)§ 9148 75 0·44 (0·35 to 0·55) 0·64 (0·50 to 0·82) 0·26 (0·20 to 0·35) 74% (65 to 80)
Vaccine dose 1 (14–20 days) 4219 40 0·46 (0·34 to 0·63) 0·60 (0·43 to 0·83) 0·25 (0·17 to 0·36) 75% (64 to 83)
Vaccine dose 1 (21–27 days) 1179 15 0·56 (0·34 to 0·94) 0·47 (0·28 to 0·79) 0·21 (0·11 to 0·39) 79% (61 to 89)
Vaccine dose 1 (28–34 days) 498 ≤5 0·28 (0·09 to 0·86) 0·16 (0·05 to 0·50) 0·07 (0·02 to 0·27) 93% (73 to 98)
Vaccine dose 1 (35–41 days) 242 5 1·03 (0·43 to 2·48) 0·36 (0·14 to 0·91) 0·16 (0·05 to 0·49) 84% (51 to 95)
Vaccine dose 1 (42+ days) 334 11 1·82 (1·00 to 3·28) 0·62 (0·34 to 1·15) 0·28 (0·13 to 0·58) 72% (42 to 87)
≥80 years
Unvaccinated 38 439 1807 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 3072 96 0·68 (0·55 to 0·83) 0·44 (0·36 to 0·55) 0·26 (0·20 to 0·32) 74% (68 to 80)
Vaccine dose 1 (7–13 days)§ 3876 128 0·73 (0·61 to 0·88) 0·63 (0·52 to 0·77) 0·34 (0·27 to 0·41) 66% (59 to 73)
Vaccine dose 1 (14–20 days) 3749 89 0·53 (0·43 to 0·65) 0·54 (0·43 to 0·68) 0·31 (0·24 to 0·39) 69% (61 to 76)
Vaccine dose 1 (21–27 days) 3172 45 0·32 (0·23 to 0·42) 0·35 (0·26 to 0·49) 0·21 (0·15 to 0·30) 79% (70 to 85)
Vaccine dose 1 (28–34 days) 1894 24 0·28 (0·18 to 0·41) 0·30 (0·19 to 0·46) 0·17 (0·11 to 0·28) 83% (72 to 89)
Vaccine dose 1 (35–41 days) 782 9 0·24 (0·13 to 0·47) 0·21 (0·11 to 0·41) 0·13 (0·06 to 0·27) 87% (73 to 94)
Vaccine dose 1 (42+ days) 548 10 0·37 (0·20 to 0·69) 0·24 (0·13 to 0·46) 0·15 (0·07 to 0·32) 85% (68 to 93)
BNT162b2 (Pfizer–BioNTech)
18–64 years
Unvaccinated 642 027 3277 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 5157 9 0·28 (0·14 to 0·53) 0·18 (0·09 to 0·36) 0·22 (0·15 to 0·34) 78% (66 to 85)
Vaccine dose 1 (7–13 days)§ 5757 46 1·30 (0·97 to 1·73) 0·84 (0·62 to 1·14) 1·06 (0·88 to 1·27) –6% (–27 to 12)
Vaccine dose 1 (14–20 days) 5141 24 0·79 (0·53 to 1·19) 0·49 (0·32 to 0·74) 0·58 (0·44 to 0·75) 42% (25 to 56)
Vaccine dose 1 (21–27 days) 4663 12 0·44 (0·25 to 0·78) 0·27 (0·15 to 0·48) 0·37 (0·26 to 0·53) 63% (47 to 74)
Vaccine dose 1 (28–34 days) 3804 ≤5 0·14 (0·04 to 0·42) 0·08 (0·03 to 0·27) 0·08 (0·03 to 0·18) 92% (82 to 97)
Vaccine dose 1 (35–41 days) 2773 7 0·43 (0·21 to 0·91) 0·25 (0·11 to 0·54) 0·37 (0·24 to 0·59) 63% (41 to 76)
Vaccine dose 1 (42+ days) 5161 11 0·37 (0·20 to 0·67) 0·23 (0·12 to 0·42) 0·32 (0·22 to 0·47) 68% (53 to 78)
65–79 years
Unvaccinated 76 418 1994 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 4487 13 0·11 (0·07 to 0·19) 0·12 (0·07 to 0·20) 0·07 (0·03 to 0·13) 93% (87 to 97)
Vaccine dose 1 (7–13 days)§ 4580 39 0·33 (0·24 to 0·46) 0·42 (0·30 to 0·58) 0·23 (0·15 to 0·34) 77% (66 to 85)
Vaccine dose 1 (14–20 days) 1904 21 0·38 (0·25 to 0·59) 0·36 (0·23 to 0·56) 0·20 (0·12 to 0·34) 80% (66 to 88)
Vaccine dose 1 (21–27 days) 399 5 0·40 (0·17 to 0·97) 0·14 (0·06 to 0·36) 0·09 (0·03 to 0·27) 91% (73 to 97)
Vaccine dose 1 (28–34 days) 278 ≤5 0·36 (0·11 to 1·10) 0·12 (0·04 to 0·36) 0·07 (0·02 to 0·27) 93% (73 to 98)
Vaccine dose 1 (35–41 days) 188 5 0·91 (0·38 to 2·20) 0·23 (0·09 to 0·58) 0·14 (0·05 to 0·43) 86% (57 to 95)
Vaccine dose 1 (42+ days) 329 11 1·20 (0·66 to 2·17) 0·38 (0·21 to 0·71) 0·24 (0·12 to 0·50) 76% (50 to 88)
(Table 3 continues on next page)
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across other countries with similar national vaccination 
programmes using these same vaccines.
Our study also had several limitations. First, we 
estimated vaccine effect against COVID-19 hospital 
admission. However, there are other outcomes of 
interest, including general practice and accident and 
emergency department consultations, intensive care 
unit admissions, deaths, and rate of secondary 
SARS-CoV-2 infections within households, in addition 
to maternal and neonatal outcomes. We did not 
estimate vaccine effect against these outcomes. Second, 
although our vaccine effect estimates were adjusted for 
potential confounders and despite the reassurance 
provided by the falsification of exposure sensitivity 
analysis, unmeasured confounders could still have 
influenced our estimates. Furthermore, given the 






Full and inverse 
propensity weighting 
adjusted RRs (95% CI)‡
Vaccine programme 
effect (95% CI)
(Continued from previous page)
≥80 years
Unvaccinated 15 963 1400 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 497 12 0·27 (0·16 to 0·48) 0·14 (0·08 to 0·24) 0·11 (0·06 to 0·21) 89% (79 to 94)
Vaccine dose 1 (7–13 days)§ 654 34 0·60 (0·43 to 0·85) 0·28 (0·20 to 0·40) 0·18 (0·12 to 0·27) 82% (73 to 88)
Vaccine dose 1 (14–20 days) 640 26 0·47 (0·32 to 0·70) 0·25 (0·17 to 0·37) 0·15 (0·10 to 0·24) 85% (76 to 90)
Vaccine dose 1 (21–27 days) 611 21 0·40 (0·26 to 0·62) 0·23 (0·15 to 0·36) 0·15 (0·09 to 0·25) 85% (75 to 91)
Vaccine dose 1 (28–34 days) 503 13 0·30 (0·17 to 0·52) 0·19 (0·11 to 0·34) 0·12 (0·06 to 0·24) 88% (76 to 94)
Vaccine dose 1 (35–41 days) 331 8 0·28 (0·14 to 0·56) 0·18 (0·09 to 0·38) 0·13 (0·06 to 0·30) 87% (70 to 94)
Vaccine dose 1 (42+ days) 506 9 0·21 (0·11 to 0·40) 0·22 (0·11 to 0·43) 0·15 (0·07 to 0·34) 85% (66 to 93)
ChAdOx1 (Oxford–AstraZeneca)
18–64 years
Unvaccinated 626 849 3293 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 1473 9 0·72 (0·37 to 1·39) 0·52 (0·26 to 1·02) 0·82 (0·56 to 1·20) 18% (-20 to 44)
Vaccine dose 1 (7–13 days)§ 910 9 1·20 (0·62 to 2·30) 0·81 (0·41 to 1·58) 0·99 (0·64 to 1·52) 1% (–52 to 36)
Vaccine dose 1 (14–20 days) 317 ≤5 0·40 (0·06 to 2·87) 0·28 (0·04 to 2·03) 0·25 (0·06 to 1·06) 75% (–6 to 94)
Vaccine dose 1 (21–27 days) 105 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
Vaccine dose 1 (28–34 days) 55 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
Vaccine dose 1 (35–41 days) 24 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
Vaccine dose 1 (42+ days) 5 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
65–79 years
Unvaccinated 81 523 2194 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 4761 29 0·22 (0·15 to 0·32) 0·24 (0·16 to 0·35) 0·12 (0·08 to 0·19) 88% (81 to 92)
Vaccine dose 1 (7–13 days)§ 4567 36 0·28 (0·20 to 0·39) 0·45 (0·31 to 0·63) 0·21 (0·14 to 0·31) 79% (69 to 86)
Vaccine dose 1 (14–20 days) 2316 19 0·28 (0·18 to 0·44) 0·46 (0·29 to 0·74) 0·21 (0·12 to 0·37) 79% (63 to 88)
Vaccine dose 1 (21–27 days) 780 10 0·42 (0·22 to 0·78) 0·69 (0·37 to 1·32) 0·32 (0·15 to 0·69) 68% (31 to 85)
Vaccine dose 1 (28–34 days) 220 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
Vaccine dose 1 (35–41 days) 55 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
Vaccine dose 1 (42+ days) 5 0 0·00 (0·00 to NA) 0·00 (0·00 to NA) 0·00 (0·00 to NA) 100% (NA to 100)
≥80 years
Unvaccinated 35 266 1765 1 (ref) 1 (ref) 1 (ref) 0
Vaccine dose 1 (0–6 days)§ 2493 84 0·69 (0·56 to 0·86) 0·50 (0·40 to 0·63) 0·28 (0·22 to 0·36) 72% (64 to 78)
Vaccine dose 1 (7–13 days)§ 3221 94 0·61 (0·50 to 0·75) 0·64 (0·51 to 0·81) 0·37 (0·29 to 0·47) 63% (53 to 71)
Vaccine dose 1 (14–20 days) 3109 63 0·43 (0·33 to 0·55) 0·56 (0·42 to 0·74) 0·37 (0·28 to 0·50) 63% (50 to 72)
Vaccine dose 1 (21–27 days) 2561 24 0·20 (0·13 to 0·29) 0·30 (0·19 to 0·47) 0·23 (0·14 to 0·37) 77% (63 to 86)
Vaccine dose 1 (28–34 days) 1391 11 0·16 (0·09 to 0·30) 0·26 (0·14 to 0·50) 0·19 (0·09 to 0·40) 81% (60 to 91)
Vaccine dose 1 (35–41 days) 451 ≤5 0·04 (0·01 to 0·32) 0·07 (0·01 to 0·53) 0·05 (0·00 to 0·56) 95% (44 to 100)
Vaccine dose 1 (42+ days) 42 ≤5 0·48 (0·07 to 3·39) 0·84 (0·12 to 6·03) 0·64 (0·07 to 6·24) 36% (–524 to 93)
Poisson regression was used to provide all adjusted estimates. Individuals who had previously tested positive were excluded. RR=rate ratios. NA=not applicable. rtPCR=real-
time reverse-transcription-PCR. *Adjusted for age. †Adjusted for time (in weeks), age, sex, Scottish Index of Multiple Deprivation, number of rtPCR tests before vaccination, 
and number of underlying medical conditions. ‡Adjusted for time (in weeks), age, sex, Scottish Index of Multiple Deprivation, number of rtPCR tests before vaccination, 
number of underlying medical conditions, and inverse propensity of being vaccinated. §Any effects observed in less than 14 days are mainly due to vaccine programme effects. 
Table 3: COVID-19 hospital admissions and days post-vaccination by age group and vaccination status and type
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limited period of follow-up, we did not attempt to 
identify a peak vaccine effect estimate for each vaccine. 
Finally, we were unable to compare vaccine effects 
between the two vaccines; this is primarily because of 
the non-experimental design of our study and because 
the target population differed between vaccines in this 
initial roll-out period.
Additional non-vaccine effects on hospital admissions 
could have resulted in potential bias. These included 
new lockdowns and changes from tier restrictions to 
full lockdowns across Scotland. However, partial 
lockdowns were present before the start of the 
vaccination programme and a full lockdown for the 
entire  population—including those vaccinated—began 
on Dec 26, 2020, and was reinforced on Jan 5, 2021. 
Overall, data available from UK serial surveys to the 
Scottish Government and Public Health Scotland 
suggested good compliance with these partial and full 
lockdowns,18 which are unlikely to have been operating 
differentially between vaccinated and unvaccinated 
people with the exception of health-care workers and 
social-care workers because they were considered 
essential workers. We adjusted for time to adjust for 
any impact on the effect of these interventions and the 
course of the pandemic on our estimates of vaccine 
effects. Other limitations of our study include the 
ChAdOx1 vaccine being predominantly used in older 
people and available only from Jan 4, 2021, giving less 
time for follow-up. Finally, although we had large 
population samples, an insufficient number of people 
had received the second dose of the vaccines to reliably 
study vaccine effect after receiving a full course of 
vaccination. However, the vaccine effect of a single dose 
is of policy interest when considering the ongoing 
debate over whether to defer a second dose to allow 
more rapid population coverage.
There are likely to be mechanisms that have 
contributed mainly to the early (<14 days) effects we 
observed in most age groups. We believe that these 
effects might be due to the way in which the 
Scottish vaccination programme was conceptualised 
and operationalised. Notably, individuals who were 
prioritised for vaccination received a written invitation 
to attend for a scheduled appointment about 14 days 
before the vaccination date. However, they were asked 
to reschedule their appointment if they had recently 
(within the past 4 weeks) had symptoms suggestive of 
COVID-19, a positive COVID-19 test, or were self-
isolating. They also received written advice emphasising 
the importance of behavioural measures to minimise 
the risk of contracting the SARS-CoV-2 virus. 
Furthermore, at the time of the vaccination, additional 
checks were made to ensure that they had not recently 
had suggested or confirmed COVID-19 and the 
behavioural advice was reinforced both verbally and 
with an additional leaflet. Possible explanations for 
these early effects therefore include: (1) a time-limited 
healthy vaccinated bias arising from the instruction 
that those who recently had COVID-19, tested positive, 
or were self-isolating were asked to defer vaccination;19 
(2) reinforcement of the importance of following 
behavioural advice before and during vaccination;19,20 
(3) early responses in those who were not SARS-CoV-2 
naive (>10% of the Scottish population);21,22 and (4) a 
time-independent healthy vaccinated bias in which 
vaccines might not have been offered to or were 
declined by the most frail.23 We attempted to adjust for 
the time-independent healthy vaccinated effect using a 
functional variable, namely dementia.14 We had hoped 
to use additional functional variables such as nursing 
home residency and need for home help, but these 
variables were not available to us.
By contrast, the later observed effects (>14 days) are 
much more likely to be mainly driven by traditional 
vaccine effects because the impact of the vaccine 
programme effects are likely to have waned by this 
timepoint. However, our main timepoint of interest, 
namely 28–34 days, probably reflects the true effects of 
the vaccine.
Monitoring the effect of currently licensed vaccines in 
the general population needs to be continued in 
Scotland and the other UK nations, especially in high-
risk subgroups such as those in care homes where more 
data will be needed to produce reliable vaccine effect 
estimates. Similarly, further monitoring is required to 
assess the effect of receiving two doses rather than 
one dose. Robust observational epidemiological studies 
should be carried out to measure the coverage of these 
newly introduced vaccines in relation to demographic 
and other population characteristics and to detect 
adverse events. These post-marketing observational 
studies will add value to the pre-licensure clinical trials 
as they can assess so-called real-life effects of the 
COVID-19 vaccines and the effect of the vaccination 
programme at a population level. We plan in due course 
to report on the effectiveness of the first dose on 
mortality and adverse events associated with the first 
dose. We also plan to report on any possible waning of 
the first-dose effects, on post-vaccine first-dose 
COVID-19 hospital admissions and deaths, and on 
second-dose effects.
In summary, we provide national evidence that the roll-
out of the first doses of the BNT162b2 mRNA and 
ChAdOx1 vaccines were associated with reductions in 
hospital admissions due to COVID-19 in high-risk adults 
in Scotland.
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